TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06434610: A Multicenter, Randomized, Double-blind, Parallel-controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of B013 Combined With Paclitaxel in the Treatment of Platinum-resistant Recurrent Ovarian Cancer, F

Sponsor: Shanghai Jiaolian Drug Research and Development Co., Ltd · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 90 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$8,500,800

Rescue Site Savings

+$5,590,200

Unlock Full NCT06434610 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06434610 Rescue Dossier →